Company intelligence / Profile preview

EpiDestiny

Cleveland, Ohio, United Statesepidlife.com ↗

Ownership: Private
Employees: ~1
Development stage: Phase 1

Overview

Currently conducting Phase 1 clinical trials for their lead program EPI01, an oral combination of decitabine and tetrahydrouridine for sickle cell disease. The therapy aims to increase fetal hemoglobin production to replace sickle cell hemoglobin.

Therapeutic areas: Hematology
Modalities: Small molecules (oral combination therapy)
Industry: Biotech

Drug pipeline

1 asset

EPI01

Phase 1

Indications: Sickle cell disease, Beta-thalassemia

Partnerships

Novo Nordisk A/S ($400 million licensing deal for EPI01)

Beyond the preview

Go deeper on EpiDestiny.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiDestiny.

Explore the full profile